Immunotherapy for lung cancer: Ongoing clinical trials

Future Oncology

Volumn 10, Issue 1, 2014, Pages 91-105

  Declerck, Sarah ^a   Vansteenkiste, Johan ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

cancer vaccine; dendritic cell; immunotherapy; lung cancer; randomized controlled trial

Indexed keywords

AGATOLIMOD; B7 ANTIGEN; BCG VACCINE; BELAGENPUMATUCEL L; CARBOPLATIN; CD28 ANTIGEN; CD86 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; GAMMA INTERFERON; GANGLIOSIDE; GEMCITABINE; INTERLEUKIN 12; INTERLEUKIN 2; IPILIMUMAB; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MELANOMA ANTIGEN 3; MONOCLONAL ANTIBODY; MUCIN 1; NIVOLUMAB; PACLITAXEL; PROGRAMMED DEATH 1 RECEPTOR; RACOTUMOMAB; TALACTOFERRIN; TECEMOTIDE; TG 4010; TRANSFORMING GROWTH FACTOR BETA2; VIRUS VECTOR; CANCER VACCINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPIDERMAL GROWTH FACTOR; L-BLP25; MAGEA3 PROTEIN, HUMAN; MEMBRANE PROTEIN; TUMOR ANTIGEN; TUMOR PROTEIN;

ABDOMINAL PAIN; ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CHEMORADIOTHERAPY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DISEASE FREE INTERVAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG RESISTANCE; DRUG SAFETY; DRUG TOLERABILITY; FEVER; FLU LIKE SYNDROME; GENE EXPRESSION; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOMODULATION; INJECTION SITE REACTION; MAINTENANCE THERAPY; MELANOMA; MONOTHERAPY; NON SMALL CELL LUNG CANCER; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SURVIVAL RATE; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION; TUMOR MICROENVIRONMENT; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; IMMUNOTHERAPY; LUNG NEOPLASMS; PROCEDURES;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; CTLA-4 ANTIGEN; EPIDERMAL GROWTH FACTOR; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS;

EID: 84894054771     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.166     Document Type: Review

References (87)

1. Ferlay J, Shin HR, Bray F et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J. Cancer 127, 2893-2917 (2010).
2. Goldstraw P, Crowley J, Chansky K et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J. Thorac. Oncol. 2, 706-714 (2007).
3. Scagliotti G, Parikh P, Von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced stage non-small cell lung cancer. J. Clin. Oncol. 26, 3543-3551 (2008).
4. Rosell R, Moran T, Queralt C et al. Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med. 361, 958-967 (2009).
5. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010).
6. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411-422 (2010).
7. Finn OJ. Cancer immunology. N. Engl. J. Med. 358, 2704-2715 (2008).
8. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 392, 245-252 (1998).
9. Kelly RJ, Gulley JL, Giaccone G. Targeting the immune system in non-small cell lung cancer: bridging the gap between promising concept and therapeutic reality. Clin. Lung Cancer 11, 228-237 (2010).
10. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 14, 233-258 (1996).
11. Raez LE, Fein S, Podack ER. Lung cancer immunotherapy. Clin. Med. Res. 3, 221-228 (2005).
12. Fong L, Small EJ. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J. Clin. Oncol. 26, 5275-5283 (2008).
13. Igney FH, Krammer PH. Immune escape of tumors: apoptosis resistance and tumor counterattack. J. Leukoc. Biol. 71, 907-920 (2002).
14. Hiraoka K, Miyamoto M, Cho Y et al. Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small cell lung carcinoma. Br. J. Cancer (2006).
15. Al-Shibli KI, Donnem T, Al-Saad S et al. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin. Cancer Res. 14, 5220-5227 (2008).
16. Kawai O, Ishii G, Kubota K et al. Predominant infiltration of macrophages and CD8+ T cells in cancer nests is a significant predictor of survival in stage IV non-small cell lung cancer. Cancer 113, 1387-1395 (2008).
17. Petersen RP, Campa MJ, Sperlazza J et al. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 107, 2866-2872 (2006).
18. Shimizu K, Nakata M, Hirami Y et al. Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. J. Thorac. Oncol. 5, 585-590 (2010).
19. Pirker R, Pereira JR, Szczesna A et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomized Phase III trial. Lancet 373, 1525-1531 (2009).
20. Decoster L, Wauters I, Vansteenkiste J. Vaccination therapy for non-small cell lung cancer: review of agents in Phase III development. Ann. Oncol. 23, 1387-1393 (2012).
21. Takahashi K, Shichijo S, Noguchi M et al. Identification of MAGE-1 and MAGE-4 proteins in spermatogonia and primary spermatocytes of testis. Cancer Res. 55, 3478-3482 (1995).
22. Gure AO, Chua R, Williamson B et al. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin. Cancer Res. 11, 8055-8062 (2005).
23. Sienel W, Varwerk C, Linder A et al. Melanoma associated antigen (MAGE)-A3 expression in stages I and II non-small cell lung cancer: results of a multi-center study. Eur. J. Cardiothorac. Surg. 25, 131-134 (2004).
24. Vansteenkiste J, Zielinski M, Linder A et al. Adjuvant MAGE-A3 immunotherapy in resected non-small cell lung cancer: Phase II randomized study results. J. Clin. Oncol. 31, 2396-2403 (2013).
25. Ulloa-Montoya F, Louahed J, Dizier B et al. Predictive gene signature in MAGEA3 antigen-specific cancer immunotherapy. J. Clin. Oncol. 31, 2388-2395 (2013).
26. Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small cell lung cancer: current knowledge and future directions. J. Clin. Oncol. 23, 2556-2568 (2005).
27. Gonzalez G, Crombet T, Catala M et al. A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial. Ann. Oncol. 9, 431-435 (1998).
28. Neninger Vinageras E, De La Torre A, Osorio Rodriguez M et al. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small cell lung cancer. J. Clin. Oncol. 26, 1452-1458 (2008).
29. Rodriguez PC, Rodriguez G, Gonzalez G et al. Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for non-small cell lung cancer therapy. MEDICC Rev. 12, 17-23 (2010).
30. Vlad AM, Kettel JC, Alajez NM et al. MUC1 immunobiology: from discovery to clinical applications. Adv. Immunol. 82, 249-293 (2004).
31. Sangha R, Butts C. L-BLP25: a peptide vaccine strategy in non-small cell lung cancer. Clin. Cancer Res. 13, 4652s-4654s (2007).
32. Raina D, Ahmad R, Kumar S et al. MUC1 oncoprotein blocks nuclear targeting of c-Abl in the apoptotic response to DNA damage. EMBO J. 25, 3774-3783 (2006).
33. Li Y, Liu D, Chen D et al. Human DF3/MUC1 carcinoma-associated protein functions as an oncogene. Oncogene 22, 6107-6110 (2003).
34. Yin L, Li Y, Ren J et al. Human MUC1 carcinoma antigen regulates intracellular oxidant levels and the apoptotic response to oxidative stress. J. Biol. Chem. 278, 35458-35464 (2003).
35. Ramlau R, Quoix E, Rolski J et al. A Phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV non-small cell lung cancer. J. Thorac. Oncol. 3, 735-744 (2008).
36. Agrawal B, Krantz MJ, Reddish MA et al. Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nat. Med. 4, 43-49 (1998).
37. Quoix E, Ramlau R, Westeel V et al. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small cell lung cancer: a controlled Phase 2B trial. Lancet Oncol. 12, 1125-1133 (2011).
38. Vivier E, Tomasello E, Baratin M et al. Functions of natural killer cells. Nat. Immunol. 9, 503-510 (2008).
39. Butts C, Murray N, Maksymiuk A et al. Randomized Phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small cell lung cancer. J. Clin. Oncol. 23, 6674-6681 (2005).
40. Grant SC, Kris MG, Houghton AN et al. Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guerin. Clin. Cancer Res. 5, 1319-1323 (1999).
41. Giaccone G, Debruyne C, Felip E et al. Phase III study of adjuvant vaccination with Bec2/Bacille Calmette-Guerin in responding patients with limited-disease small cell lung cancer (EORTC 08971-08971B; Silva study). J. Clin. Oncol. 23, 6854-6864 (2005).
42. Malykh YN, Schauer R, Shaw L. N-glycolylneuraminic acid in human tumours. Biochimie 83, 623-634 (2001).
43. Vazquez AM, Hernandez AM, Macias A et al. Racotumomab: an anti-idiotype vaccine related to N-glycolyl-containing gangliosides - preclinical and clinical data. Front. Oncol. 2, 150 (2012).
44. Diaz Y, Gonzalez A, Lopez A et al. Anti-ganglioside anti-idiotypic monoclonal antibody-based cancer vaccine induces apoptosis and antiangiogenic effect in a metastatic lung carcinoma. Cancer Immunol. Immunother. 58, 1117-1128 (2009).
45. Neninger E, Diaz RM, De La Torre A et al. Active immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell lung cancer: report of a Phase I trial. Cancer Biol. Ther. 6, 145-150 (2007).
46. Alfonso S, Diaz RM, De La Torre A et al. 1E10 anti-idiotype vaccine in non-small cell lung cancer: experience in stage IIIb/IV patients. Cancer Biol. Ther. 6, 1847-1852 (2007).
47. Nemunaitis J, Sterman D, Jablons D et al. Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small cell lung cancer. J. Natl. Cancer Inst. 96, 326-331 (2004).
48. Nemunaitis J, Dillman RO, Schwarzenberger PO et al. Phase II study of belagenpumatucel-L, a transforming growth factor β-2 antisense gene-modified allogeneic tumor cell vaccine in non-small cell lung cancer. J. Clin. Oncol. 24, 4721-4730 (2006).
49. Fakhrai H, Tong A, Nemunaitis J et al. Correlation of immune responses and survival in a Phase II study of belagenpumatucel-L in non-small cell lung cancer. J. Clin. Oncol. 17, Abstract 3013 (2011).
50. Gail MH. A placebo-controlled randomized double-blind study of adjuvant intrapleural BCG in patients with resected T1N0, T1N1, or T2N0 squamous cell carcinoma, adenocarcinoma, or large cell carcinoma of the lung. LCSG Protocol 771. Chest 106, 287S-292S (1994).
51. Holmes EC. Surgical adjuvant therapy for stage II and stage III adenocarcinoma and large cell undifferentiated carcinoma. Chest 106, 293S-296S (1994).
52. Jansen RL, Slingerland R, Goey SH et al. Interleukin-2 and interferon-α in the treatment of patients with advanced non-small cell lung cancer. J. Immunother. 12, 70-73 (1992).
53. Hirsh V, Paz-Ares L, Boyer M et al. Randomized Phase III trial of paclitaxel/carboplatin with or without PF-3512676 (toll-like receptor 9 agonist) as first-line treatment for advanced non-small cell lung cancer. J. Clin. Oncol. 29, 2667-2674 (2011).
54. Manegold C, Van Zandwijk N, Szczesna A et al. A Phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small cell lung cancer. Ann. Oncol. 23, 72-77 (2012).
55. Parikh PM, Vaid A, Advani SH et al. Randomized, double-blind, placebo-controlled Phase II study of single-agent oral Talactoferrin in patients with locally advanced or metastatic non-small cell lung cancer that progressed after chemotherapy. J. Clin. Oncol. 29, 4129-4136 (2011).
56. Digumarti R, Wang Y, Raman G et al. A randomized, double-blind, placebo-controlled, Phase II study of oral Talactoferrin in combination with carboplatin and paclitaxel in previously untreated locally advanced or metastatic non-small cell lung cancer. J. Thorac. Oncol. 6, 1098-1103 (2011).
57. Ramalingam SS, Crawford J, Chang A et al. FORTIS-M, a randomized, double-blind, placebo-controlled Phase 3 study of oral Talactoferrin alfa with best supportive care in patients with advanced non-small cell lung cancer following two or more prior regimens-by the FORTIS-M study group. Ann. Oncol. 23(Suppl. 9), 2347 (2013).
58. Kavanagh B, O'Brien S, Lee D et al. CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood 112, 1175-1183 (2008).
59. Maker AV, Attia P, Rosenberg SA. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J. Immunol. 175, 7746-7754 (2005).
60. Wolchok JD, Hoos A, O'Day S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15, 7412-7420 (2009).
61. Lynch TJ, Bondarenko I, Luft A et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small cell lung cancer: results from a randomized, double-blind, multicenter Phase II study. J. Clin. Oncol. 30, 2046-2055 (2012).
62. Reck M, Bondarenko I, Luft A et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease small cell lung cancer: results from a randomized, double-blind, multicenter Phase 2 trial. Ann. Oncol. 24, 75-83 (2013).
63. Keir ME, Butte MJ, Freeman GJ et al. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26, 677-704 (2008).
64. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252-264 (2012).
65. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012).
66. Hamid O, Schmidt H, Nissan A et al. A prospective Phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J. Transl. Med. 9, 204-209 (2011).
67. Gettinger S, Antonia SJ, Spigel D et al. Clinical activity and safety of anti-programmed death (PD-1) (BMS-936558/MDX-1106/ONO-4538) in patients (pts) with advanced non-small cell lung cancer (NSCLC). Ann. Oncol. 23(Suppl. 9), Abstract 1237 (2013).
68. Topalian SL, Sznol M, Brahmer JR et al. Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with advanced solid tumors: survival and long-term safety in a Phase I trial. J. Clin. Oncol. 31, Abstract 3002 (2013).
69. Ramakrishnan R, Gabrilovich DI. Novel mechanism of synergistic effects of conventional chemotherapy and immune therapy of cancer. Cancer Immunol. Immunother. 62, 405-410 (2013).
70. Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J. Natl. Cancer Inst. 105, 256-265 (2013).
71. Mellstedt H, Vansteenkiste J, Thatcher N. Vaccines for the treatment of non-small cell lung cancer: Investigational approaches and clinical experience. Lung Cancer 73, 11-17 (2011).
72. GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer. http://clinicaltrials.gov/ct2/show/NCT00480025?term=NCT00480025&rank=1
73. Vaccine Therapy in Treating Patients With Non-Small Cell Lung Cancer (NSCLC) Stages IIIB/IV. http://clinicaltrials.gov/ct2/show/NCT00516685?term=NCT00516685&rank=1
74. Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer (TIME). http://clinicaltrials.gov/ct2/show/NCT01383148?term=NCT01383148&rank=1
75. Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START). http://clinicaltrials.gov/ct2/show/NCT00409188?term=NCT00409188&rank=1
76. Merck: Phase III trial of L-BLP25 (stimuvax) in patients with non-small cell lung cancer did not meet primary endpoint. http://news.merck.de/N/0/EB4A46A2AC4A52E7C1257AD9001F3186/$File/StimuEng.pdf
77. Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population (INSPIRE). http://clinicaltrials.gov/ct2/show/NCT01015443?term=NCT01015443&rank=1
78. Immunotherapy With Racotumomab in Advanced Lung Cancer. http://clinicaltrials.gov/ct2/show/NCT01460472?term=NCT01460472&rank=1
79. Immunotherapy With Racotumomab Versus Support Treatment in Advanced Non-small Cell Lung Cancer Patients. http://clinicaltrials.gov/ct2/show/NCT01240447?term=NCT01240447&rank=1
80. Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy (STOP). http://clinicaltrials.gov/ct2/show/NCT00676507?term=NCT00676507&rank=1
81. Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer (FORTIS-C). http://clinicaltrials.gov/ct2/show/NCT00706862?term=NCT00706862&rank=1
82. Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin. http://clinicaltrials.gov/ct2/show/NCT01285609?term=NCT01285609&rank=1
83. Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone. http://clinicaltrials.gov/ct2/show/NCT01450761?term=NCT01450761&rank=1
84. Study of BMS-936558 Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC). http://clinicaltrials.gov/ct2/show/NCT01642004?term=NCT01642004&rank=1
85. Study of BMS-936558 Compared to Docetaxel in Previously Treated Advanced or Metastatic Non-squamous NSCLC. http://clinicaltrials.gov/ct2/show/NCT01673867?term=NCT01673867&rank=1
86. Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in First-Line or in Switch Maintenance in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012). http://clinicaltrials.gov/ct2/show/NCT01454102?term=NCT01454102&rank=1
87. A Randomized Trial to Study the Safety and Efficacy of EGF Cancer Vaccination in Latestage (IIIB/IV) Non-small Cell Lung Cancer Patients (NSCLC). http://clinicaltrials.gov/ct2/show/NCT01444118?term=NCT01444118&rank=1